CAR T cell therapy has impressive achievements in the arena of hematological malignancies, in which seven CAR T products have been approved by the FDA (13), starting from the first CAR-T drug Kymriah® (tisagenlecleucel, Novartis) in August 2017 for acute B lymphocytic leukemia (14) to most recently CARVYKTITM (ciltacabtagene autoleucel, Legend Biotech) for CD19-positive relapsed or refractory diffuse large B-cell lymphoma in February 2022 (15). Here, CD19 is linked to diffuse large B-cell lymphoma.